Menu Close


SeqOne Genomics was founded in 2017 and develops state-of-the-art genomics analysis tools for clinical applications in the fields of cancer and rare diseases.

The company’s flagship product, SeqOne/Platform is a cloud-based end-to-end solution that reduces the turnaround time and cost required to deliver accurate genetic analyses, for use in mainstream medicine.

SeqOne has already secured a user base in a wide range of healthcare establishments including hospitals and private sector testing laboratories.

They assembled a young and multidisciplinary team and focus on making personalized medicine more readily available.

In January 2022 SeqOne Genomics closed a 20 million euros series A to accelerate the deployment of their platform.

SeqOne 2
SeqOne 1




investment / alumnus




committed team

David Devigne

Other portfolio companies within OMX Europe Venture Fund